Forty-four states have brought a lawsuit against the industry.
News & Analysis: Mylan
MYL earnings call for the period ending March 31, 2019.
The drugmaker's challenges in the U.S. generics market and problems at a manufacturing facility weighed on its first-quarter revenue and earnings.
The drugmaker's Q1 update is weighing on its share price.
A little-changed market still left these stocks lower.
The drugmaker's Q4 update had very few bright spots.
The drugmaker's revenue and earnings fell because of continued weakness in the U.S. market.
MYL earnings call for the period ending December 31, 2018.
Find out how these stocks fared on Election Day.
Better-than-expected Q3 earnings generated excitement for the drugmaker.